Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW OKs 60 New APIs in 2014, Doubling from Year Ago
February 26, 2015
- MHLW Prods Self-Inspections at Insurance Pharmacies after Medication History Fuss
February 25, 2015
- Drug Price Settlement Rate at 76.2% in December: MHLW
February 24, 2015
- Shelved Decision on Xarelto Recommendation Doesn’t Mean Disapproval: MHLW
February 24, 2015
- New Division for Cancer and Specific Diseases Control to Handle Hepatitis Measures after Reorganization of HSB
February 24, 2015
- Editor’s Pick: Five Healthcare News Headlines for Feb. 9 - 22
February 23, 2015
- Shiozaki Says Annual NHI Price Cuts Could Hit Distributors, Mar Innovation Drive; Ministry to Consider Plan based on Govt’s Economic Blueprint
February 23, 2015
- PAFSC Committee’s Nod for New Xarelto Indication Put on Hold
February 23, 2015
- Drug Dispensing Expenditure Up 1.8% in April-September 2014; Down 4.1 Points from Previous Year
February 23, 2015
- Gilead’s Sofosbuvir Could Join NHI Price List in May If OK’ed by PAFSC Panel on March 5
February 20, 2015
- MHLW Picks 4 Hospitals Eligible for Special Mixed Care Scheme in Tokyo Economic Zone
February 20, 2015
- Panel OKs Intractable Disease Designation of 43 More Diseases
February 19, 2015
- Japan Generic Share at 55% in September 2014: MHLW
February 19, 2015
- Chuikyo Approves 26 Products Including Takecab, Zelboraf for Listing
February 19, 2015
- Add Risk of Interstitial Pneumonia to Eliquis Package Insert: MHLW
February 18, 2015
- Abe Calls for Shrewd Strategies for Pharmas, Industry Consolidation as Necessary
February 18, 2015
- LDP Pharma Policy Study Group on Alert for 3 Consecutive Years of Drug Price Cuts
February 17, 2015
- MHLW Approves 309 Generic Products Ahead of June Listing; 32 Companies Obtain Approval for Plavix Generics Including AGs
February 17, 2015
- Panel Approves 43 More Diseases as Designated Intractable Diseases
February 17, 2015
- Gilead Told to Improve Biz Practice in Japan over Delayed ADR Reporting
February 16, 2015
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…